Condition: Metastatic Colorectal Cancer · Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
This is a prospective, randomized, open-label, multicenter phase II investigating the therapy of Fruquintinib in combination with Tislelizumab in patients with MSS/pMMR metastatic colorectal cancer without liver metastases.
This description comes directly from the study's public registry record.
Alexander Stein, Prof. Dr. · +494036035220 · stein@hope-hamburg.de
Martin Walker · +4969589978772 · walker.martin@ikf-khnw.de
Always discuss trial participation with your own doctor first.
| Ordensklinikum Linz GmbH | Linz, Austria | Not Yet Recruiting |
| SCRI CCCIT Ges.m.b.H. | Salzburg, Austria | Recruiting |
| Noe LGA Gesundheit Thermenregion GmbH | Wiener Neustadt, Austria | Not Yet Recruiting |
| Klinikum St. Marien Amberg | Amberg, Germany | Recruiting |
| HELIOS Klinikum Bad Saarow | Bad Saarow, Germany | Recruiting |
| Charite Universitaetsmedizin Berlin KöR | Berlin, Germany | Recruiting |
| HELIOS Emil von Behring Berlin | Berlin, Germany | Recruiting |
| Katholisches Klinikum Bochum gGmbH | Bochum, Germany | Not Yet Recruiting |
| Universitätsklinikum Düsseldorf Klinik für Gastroenterologie, Hepatologie und Infektiologie Gastroonkologische Studienzentrale | Düsseldorf, Germany | Not Yet Recruiting |
| KEM | Klinik für Internistische Onkologie gGmbH | Essen, Germany | Recruiting |
| Universitätsklinikum Essen | Essen, Germany | Not Yet Recruiting |
| Goethe University Frankfurt | Frankfurt, Germany | Recruiting |
+ 11 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06856837